---
title: "Methodological considerations when defining CBL (11q23.1-3) as a prognostic biomarker in stage II"
id: "british-journal-of-cancer-0-methodological-considerations-in-defining-cbl-as-a-prognostic-biomarker-in"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-methodological-considerations-in-defining-cbl-as-a-prognostic-biomarker-in"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03628-2"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Methodological considerations when defining CBL (11q23.1-3) as a prognostic biomarker in stage II
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-methodological-considerations-in-defining-cbl-as-a-prognostic-biomarker-in
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03628-2)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The correspondence reviews Lindner et al.'s study that mapped the genetic landscape of stage II melanoma and identified **CBL** deletion (11q23.1-3) as a prognostic biomarker in a cohort of 193 therapy‑naïve patients. - The authors commend the use of a sizable, untreated cohort and a multivariate analysis that found the 11q23.1-3 (CBL) deletion to be prognostic in the overall cohort. - They highlight a specific subgroup observation in RAS‑mutated tumours where an unadjusted p = 0.044 for relapse‑free survival was reported, but the rigorously calculated adjusted p (Padj = 0.178) does not meet strict statistical significance. - The correspondence cautions that exploratory subgroup analyses across genomic subtypes (BRAF, RAS, NF1, Triple‑WT) should incorporate **multiple testing adjustment** to reduce Type I error risk. - The authors recommend aligning subgroup reporting with standardised reporting norms such as the **REMARK** guidelines to improve interpretability and reproducibility. - They note potential confounding by sub‑stage when translating cohort‑level findings into subgroup stratifications and call for careful contextualisation of subgroup inferences. - References cited include the original Lindner et al. genetic landscape study, guidance on subgroup reporting in clinical research, the Cancer Genome Atlas melanoma classification, AJCC staging revisions, and REMARK reporting recommendations. - No competing interests were declared by the correspondence authors; author affiliations are the Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University. - The piece is a correspondence published in British Journal of Cancer (21 September 2026) and focuses on methodological clarity rather than proposing new biological mechanisms.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03628-2#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03628-2) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ About the Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [correspondences](https://www.nature.com/bjc/articles?type=correspondence) 4. article * Correspondence * Published: 21 September 2026 Genetics and Genomics # Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma * [Jingyi Han](https://www.nature.com/articles/s41416-026-03628-2#auth-Jingyi-Han-Aff1)[1](https://www.nature.com/articles/s41416-026-03628-2#Aff1) [na1](https://www.nature.com/articles/s41416-026-03628-2#na1), * [Xinger Gao](https://www.nature.com/articles/s41416-026-03628-2#auth-Xinger-Gao-Aff1)[1](https://www.nature.com/articles/s41416-026-03628-2#Aff1) [na1](https://www.nature.com/articles/s41416-026-03628-2#na1) & * [Wenjun Jiang](https://www.nature.com/articles/s41416-026-03628-2#auth-Wenjun-Jiang-Aff1)[1](https://www.nature.com/articles/s41416-026-03628-2#Aff1) [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03628-2#citeas) [ Save article ](https://www.nature.com/articles/s41416-026-03628-2/save-research?_csrf=Xw7GZHBErv5moeneyh5JUNS31HU4Z4-T) [ View saved research ](https://www.nature.com/saved-research) We read with great interest the recent study by Lindner et al. [[1](https://www.nature.com/articles/s41416-026-03628-2#ref-CR1 "Lindner ES, Admard J, Demidov G, Armeanu-Ebinger S, Sinnberg T, Niessner H, et al. Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker. Br J Cancer. 2026;134:1801–9.")], which provides a comprehensive genetic landscape of stage II melanoma. We commend the authors for investigating a robust cohort of 193 therapy-naïve patients. Importantly, their rigorous multivariate analysis demonstrating the prognostic significance of the 11q23.1-3 (CBL) deletion in the overall cohort provides a compelling foundation for exploring this alteration as potential biomarker. However, as the authors seek to translate these findings into specific subgroup stratifications, a few analytical nuances regarding statistical adjustments and sub-stage confounding merit further methodological consideration. First, while the prognostic trend of the 11q23.1-3 (CBL) deletion in the RAS-mutated subgroup is intriguing, the interpretation of the statistical significance warrants careful contextualisation. The authors highlight an unadjusted _p_ = 0.044 for relapse-free survival in this subgroup; however, the rigorously calculated adjusted _p_ -value (_P_ adj = 0.178) suggests that this specific subgroup finding may not yet reach strict statistical significance. In exploratory subgroup analyses across multiple genomic subtypes (BRAF, RAS, NF1, Triple-WT), adjusting for multiple testing is generally recommended to prevent Type I errors [[2](https://www.nature.com/articles/s41416-026-03628-2#ref-CR2 "Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94.")]. Emphasising the adjusted metric aligns with standardised reporting norms (such as the REMARK guidelines) and helps readers accurately gauge the predictive robustness of this alteration within specific molecular subsets. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03628-2) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03628-2) Subscribe to this journal Receive 24 print issues and online access 251,40 € per year only 10,48 € per issue [Learn more](https://www.nature.com/bjc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03628-2) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ## References 1. Lindner ES, Admard J, Demidov G, Armeanu-Ebinger S, Sinnberg T, Niessner H, et al. Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker. Br J Cancer. 2026;134:1801–9. 2. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94. [Article](https://doi.org/10.1056%2FNEJMsr077003) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtlGisLnM) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18032770) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Statistics%20in%20medicine%E2%80%94reporting%20of%20subgroup%20analyses%20in%20clinical%20trials&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMsr077003&volume=357&pages=2189-94&publication_year=2007&author=Wang%2CR&author=Lagakos%2CSW&author=Ware%2CJH&author=Hunter%2CDJ&author=Drazen%2CJM) 3. Cancer Genome Atlas Network.Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96. [Article](https://doi.org/10.1016%2Fj.cell.2015.05.044) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genomic%20classification%20of%20cutaneous%20melanoma&journal=Cell&doi=10.1016%2Fj.cell.2015.05.044&volume=161&pages=1681-96&publication_year=2015) 4. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92. [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29028110) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978683) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Melanoma%20staging%3A%20evidence-based%20changes%20in%20the%20American%20Joint%20Committee%20on%20Cancer%20eighth%20edition%20cancer%20staging%20manual&journal=CA%20Cancer%20J%20Clin&volume=67&pages=472-92&publication_year=2017&author=Gershenwald%2CJE&author=Scolyer%2CRA&author=Hess%2CKR&author=Sondak%2CVK&author=Long%2CGV&author=Ross%2CMI) 5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4. [Article](https://doi.org/10.1093%2Fjnci%2Fdji237) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXpsVaks7s%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16106022) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Reporting%20recommendations%20for%20tumor%20marker%20prognostic%20studies%20%28REMARK%29&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdji237&volume=97&pages=1180-4&publication_year=2005&author=McShane%2CLM&author=Altman%2CDG&author=Sauerbrei%2CW&author=Taube%2CSE&author=Gion%2CM&author=Clark%2CGM) [Download references](https://citation-needed.springer.com/v2/references/10.1038/s41416-026-03628-2?format=refman&flavour=references) ## Author information Author notes 1. These authors contributed equally: Jingyi Han, Xinger Gao. ### Authors and Affiliations 1. Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, China Jingyi Han, Xinger Gao & Wenjun Jiang Authors 1. Jingyi Han [View author publications](https://www.nature.com/search?author=Jingyi%20Han) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jingyi%20Han)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jingyi%20Han%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 2. Xinger Gao [View author publications](https://www.nature.com/search?author=Xinger%20Gao) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xinger%20Gao)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xinger%20Gao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 3. Wenjun Jiang [View author publications](https://www.nature.com/search?author=Wenjun%20Jiang) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wenjun%20Jiang)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wenjun%20Jiang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Contributions Jingyi Han and Xinger Gao: Formal analysis and writing original draft. Wenjun Jiang: Conceptualisation, writing, review and editing. ### Corresponding author Correspondence to Wenjun Jiang. ## Ethics declarations ### Competing interests The authors declare no competing interests. ## Additional information **Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Methodological%20considerations%20in%20defining%20CBL%20as%20a%20prognostic%20biomarker%20in%20stage%20II%20melanoma&author=Jingyi%20Han%20et%20al&contentID=10.1038%2Fs41416-026-03628-2&copyright=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20Limited&publication=0007-0920&publicationDate=2026-09-21&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41416-026-03628-2)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41416-026-03628-2) ### Cite this article Han, J., Gao, X. & Jiang, W. Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma. _Br J Cancer_ (2026). https://doi.org/10.1038/s41416-026-03628-2 [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41416-026-03628-2?format=refman&flavour=citation) * Received: 05 June 2026 * Revised: 14 June 2026 * Accepted: 03 September 2026 * Published: 21 September 2026 * Version of record: 21 September 2026 * DOI: https://doi.org/10.1038/s41416-026-03628-2 ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative ### Subjects * [Cancer genetics](https://www.nature.com/subjects/cancer-genetics) * [Prognostic markers](https://www.nature.com/subjects/prognostic-markers) [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03628-2) [ Buy or subscribe ](https://www.nature.com/articles/s41416-026-03628-2#access-options) ## Associated content ### [Genetic landscape of stage II melanoma identifies _CBL_ as a new driver gene and prognostic biomarker](https://www.nature.com/articles/s41416-026-03394-1) * Elena Sophia Lindner * Jakob Admard * Christopher Schroeder British Journal of Cancer Article Open Access 09 Apr 2026 * Sections * References * [References](https://www.nature.com/articles/s41416-026-03628-2#Bib1) * [Author information](https://www.nature.com/articles/s41416-026-03628-2#author-information) * [Ethics declarations](https://www.nature.com/articles/s41416-026-03628-2#ethics) * [Additional information](https://www.nature.com/articles/s41416-026-03628-2#additional-information) * [Rights and permissions](https://www.nature.com/articles/s41416-026-03628-2#rightslink) * [About this article](https://www.nature.com/articles/s41416-026-03628-2#article-info) Advertisement 1. Lindner ES, Admard J, Demidov G, Armeanu-Ebinger S, Sinnberg T, Niessner H, et al. Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker. Br J Cancer. 2026;134:1801–9. 2. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94. [Article](https://doi.org/10.1056%2FNEJMsr077003) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtlGisLnM) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18032770) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Statistics%20in%20medicine%E2%80%94reporting%20of%20subgroup%20analyses%20in%20clinical%20trials&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMsr077003&volume=357&pages=2189-94&publication_year=2007&author=Wang%2CR&author=Lagakos%2CSW&author=Ware%2CJH&author=Hunter%2CDJ&author=Drazen%2CJM) 3. Cancer Genome Atlas Network.Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96. [Article](https://doi.org/10.1016%2Fj.cell.2015.05.044) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genomic%20classification%20of%20cutaneous%20melanoma&journal=Cell&doi=10.1016%2Fj.cell.2015.05.044&volume=161&pages=1681-96&publication_year=2015) 4. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92. [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29028110) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978683) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Melanoma%20staging%3A%20evidence-based%20changes%20in%20the%20American%20Joint%20Committee%20on%20Cancer%20eighth%20edition%20cancer%20staging%20manual&journal=CA%20Cancer%20J%20Clin&volume=67&pages=472-92&publication_year=2017&author=Gershenwald%2CJE&author=Scolyer%2CRA&author=Hess%2CKR&author=Sondak%2CVK&author=Long%2CGV&author=Ross%2CMI) 5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4. [Article](https://doi.org/10.1093%2Fjnci%2Fdji237) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXpsVaks7s%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16106022) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Reporting%20recommendations%20for%20tumor%20marker%20prognostic%20studies%20%28REMARK%29&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdji237&volume=97&pages=1180-4&publication_year=2005&author=McShane%2CLM&author=Altman%2CDG&author=Sauerbrei%2CW&author=Taube%2CSE&author=Gion%2CM&author=Clark%2CGM) British Journal of Cancer (_Br J Cancer_) ISSN 1532-1827 (online) ISSN 0007-0920 (print) ## nature.com footer links ### About Nature Portfolio * [About us](https://www.nature.com/npg_/company_info/index.html) * [Press releases](https://www.nature.com/npg_/press_room/press_releases.html) * [Press office](https://press.nature.com/) * [Contact us](https://support.nature.com/support/home) ### Discover content * [Journals A-Z](https://www.nature.com/siteindex) * [Articles by subject](https://www.nature.com/subjects) * [protocols.io](https://www.protocols.io/) * [Nature Index](https://www.natureindex.com/) ### Publishing policies * [Natu
## Related Clinical Research

- [Decidual-like Natural Killer Cells Enriched in Melanoma and CD9 Acquisition via Tumor Contact](https://medichelpline.com/clinical-feed/medrxiv-2-decidual-like-natural-killer-cells-are-enriched-in-melanomas-and-acquire-cd9.md)
- [Immune-pressure redistribution as a framework for resistance to PD-1/PD-L1 blockade](https://medichelpline.com/clinical-feed/pubmed-42763389.md) (DOI: 10.1186/s12943-026-02786-4)
- [LongPhase-TO: tumor-only long-read method for somatic haplotype reconstruction and variant recalib](https://medichelpline.com/clinical-feed/biorxiv-8-somatic-haplotype-reconstruction-and-variant-recalibration-from-tumor-only-long.md)
- [Cross-species spatial profiling implicates progranulin in immune-suppressive niches of brain metas](https://medichelpline.com/clinical-feed/biorxiv-0-cross-species-spatial-profiling-links-progranulin-to-an-immune-suppressive.md)
- [Lived Experience in Rare Disease Research: Shaping Outcomes for Patients](https://medichelpline.com/clinical-feed/plos-medicine-0-living-with-a-rare-disease-why-lived-experience-must-shape-research.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.